The evolution of the class of antibacterial quinolones includes the introduction in therapy of
highly successful compounds. Although many representatives were withdrawn due to …

Abstract Delafloxacin (formerly WQ-3034, ABT492, RX-3341) is a novel fluoroquinolone
chemically distinct from currently marketed fluoroquinolones with the absence of a …

Purpose Mild adverse drug reactions typically associated with antimicrobials are familiar to
most clinicians. However, rare phenomena, such as neurotoxicity, are often unpredictable …

There has been a growing rate of resistance among common urinary tract pathogens, such
as Escherichia coli, to traditional antimicrobial therapies including the “gold standard” …

Background. Although gatifloxacin is no longer available, other fluoroquinolones may
significantly interfere with glucose homeostasis. The objective of the present study was to …

The new respiratory fluoroquinolones (gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin,
and on the horizon, garenoxacin) offer many improved qualities over older agents such as …

The aim of this study was to develop novel biomedicated electrospun nanofibers for
controlled release. Pre-formulation studies were carried out for nanofibers of sodium …

The pharmacokinetic characteristics of levofloxacin, moxifloxacin, and gatifloxacin include
excellent oral bioavailability (90–99%), extensive penetration into tissues and body fluids …

The present investigation aimed at improving the ocular bioavailability of gatifloxacin by
prolonging its residence time in the eye and reducing problems associated with the drug re …

The ideal ophthalmic anti-infective exhibits broad-spectrum activity against grampositive,
gram-negative, and atypical bacterial species. These pathogens can cause potentially …